Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) — Capital Reinvestment Ratio
Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Capital Reinvestment Ratio of 97.08x as of September 2025, meaning it reinvests 97% of its operating cash flow (CN¥543.69K) in capital expenditures (CN¥52.78 Million). See cash generation quality of Suzhou Zelgen Biopharmaceuticals Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Suzhou Zelgen Biopharmaceuticals Co Ltd Capital Reinvestment Ratio (2024–2024)
This chart tracks Suzhou Zelgen Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd (2024–2024)
Year-by-year Capital Reinvestment Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd from 2024 to 2024. For live market cap and broader valuation context, see Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.50x | CN¥38.20 Million | CN¥95.69 Million | — |